机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.[3]Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.[4]Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China.[5]Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.[6]Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.四川大学华西医院[7]Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine.
Surgical treatment is the first-line treatment for Barcelona Clinic Liver Cancer (BCLC) stage 0 or A1 hepatocellular carcinoma (HCC) patients, and postoperative monitoring improves long-term survival. We aimed to establish a reasonable short-interval follow-up duration for patients with HCC.The population for this retrospective study included 1396 HCC patients with BCLC stage 0 or A1 disease who underwent curative resection from 2013 to 2016 at five centers in China. Hazard rates for recurrence were calculated using the hazard function.The recurrence rates in patients with BCLC stage 0 and A1 HCC were 46.4% and 58.0%, respectively. The hazard curve for stage 0 patients was relatively flat, and the hazard rate was consistently low (peak hazard rate 0.0163). The hazard rate curve for recurrence was initially high (peak hazard rate 0.0441) in patients with BCLC stage A1 disease and showed a rapid decreasing trend within one year, followed by a slow decreasing trend, reaching a low level (< 0.0163) at approximately 36 months. The time to get low risk was 47, 41, and 51 months in patients with cirrhosis, HBV infection, and satellite lesions, respectively.A short-interval of one year follow-up is sufficient for HCC patients with BCLC stage 0 disease, whereas a short-interval follow-up time of 3 years should be considered for patients at stage A1. The follow-up period should be appropriately prolonged for patients with cirrhosis, HBV infection, and satellite lesions. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
基金：
Clinical Research Plan of Shanghai Hospital
Development Center (No. SHDC2020CR1004A), the State Key Program of the
National Natural Science Foundation of China (No: 81730097), and the National
Natural Science Foundation of China (No: 82072618).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区医学
小类|3 区胃肠肝病学
最新[2023]版：
大类|3 区医学
小类|3 区胃肠肝病学
第一作者：
第一作者机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.[*1]Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, 200433 China
推荐引用方式(GB/T 7714)：
Xiang Yan-Jun,Wang Kang,Yu Hong-Ming,et al.Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at BCLC stage 0 or A1: A multicenter observational study[J].Hepatology research : the official journal of the Japan Society of Hepatology.2022,doi:10.1111/hepr.13811.
APA：
Xiang Yan-Jun,Wang Kang,Yu Hong-Ming,Wang Miao-Miao,Li Le-Qun...&Cheng Shu-Qun.(2022).Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at BCLC stage 0 or A1: A multicenter observational study.Hepatology research : the official journal of the Japan Society of Hepatology,,
MLA：
Xiang Yan-Jun,et al."Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at BCLC stage 0 or A1: A multicenter observational study".Hepatology research : the official journal of the Japan Society of Hepatology .(2022)
